Aliqopa: Withdrawal of the marketing authorisation application



Bayer AG withdrew its application for a marketing authorisation of Aliqopa for the treatment of adult patients with previously treated marginal zone lymphoma (MZL), a cancer of a type of white blood cells called B lymphocytes or B cells.

The company withdrew the application on 20 December 2021.

  • List item

    Questions and answers on the withdrawal of application for the marketing authorisation of Aliqopa (copanlisib) (PDF/114.84 KB)

    First published: 28/01/2022

  • Key facts

    Product number
    International non-proprietary name (INN) or common name
    • copanlisib
    Active substance
    • Copanlisib dihydrochloride
    Date of withdrawal
    Company making the application
    Bayer AG
    Withdrawal type
    Initial authorisation

    All documents

    Related content

    Related information on withdrawals

    A question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter.

    An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 120').

    How useful was this page?

    Add your rating